文献速递糖尿病

胰高血糖素样肽1受体激动剂对合并2型糖尿病的肾移植受者可能具有优势

Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

这项回顾性队列研究纳入本机构接受肾移植后随访至少24个月的2型糖尿病受者,比较胰高血糖素样肽1受体激动剂(GLP-1 RA)与其他降糖药对持续估算肾小球滤过率(eGFR)下降风险的影响。73例GLP-1 RA使用者中1例、73例非GLP-1 RA使用者中6例出现持续eGFR下降;肾移植后使用GLP-1 RA与持续eGFR下降风险较低相关。

要点

  • 本回顾性队列纳入肾移植后2型糖尿病受者,GLP-1 RA组与非GLP-1 RA组各73例。
  • 非GLP-1 RA组6例、GLP-1 RA组1例出现持续eGFR下降(较基线下降40%持续4个月)。
  • 肾移植后使用GLP-1 RA与持续eGFR下降风险较低相关,可能有助于改善移植肾存活。

核心结论

  • 肾移植后使用GLP-1 RA者持续eGFR下降风险低于非GLP-1 RA使用者,GLP-1 RA可能有助于改善肾移植后移植肾存活。

研究设计与样本

  • 本机构开展的回顾性队列研究,纳入所有肾移植后2型糖尿病受者,自移植后1个月起随访至少24个月(截至2020年12月31日)。
  • GLP-1 RA组73例,非GLP-1 RA组73例;采用逻辑回归计算启动GLP-1 RA相较于非GLP-1 RA的倾向性评分,并以逆概率治疗加权比值比控制基线混杂变量。
  • 主要结局为移植后持续至少40%的eGFR较基线下降并持续4个月;钠-葡萄糖协同转运蛋白2抑制剂使用作为竞争事件。

主要发现

  • 非GLP-1 RA组6例、GLP-1 RA组1例出现持续eGFR下降。
  • 肾移植后使用GLP-1 RA与持续eGFR下降风险较低相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have the potential to improve native kidney function. OBJECTIVE: This work aimed to elucidate the possible protective effects of GLP-1 RAs on kidney graft function after successful kidney transplantation (KTX). METHODS: This retrospective cohort study included all KTX recipients (KTRs) at our facility with type 2 diabetes who were followed up from 1 month post-transplantation for 24 months or longer as of December 31, 2020. We investigated associations between the use of GLP-1 RAs and other antidiabetic medications (non-GLP-1 RAs) and the risk of sustained estimated glomerular filtration rate (eGFR) reduction (40% reduction compared with baseline for 4 months) for KTRs with type 2 diabetes. We calculated the propensity score of initiating GLP-1 RAs compared with that of initiating non-GLP-1 RAs as a function of baseline covariates using logistic regression. The inverse probability of the treatment-weighted odds ratio was estimated to control for baseline confounding variables. Sodium-glucose cotransporter 2 inhibitor use was a competing event. The primary outcome was sustained eGFR reduction of at least 40% from baseline for 4 months post-transplantation. RESULTS: Seventy-three patients were GLP-1 RA users and 73 were non-GLP-1 RA users. Six patients and 1 patient in the non-GLP-1 RA and GLP-1 RA groups had sustained eGFR reduction. GLP-1 RA use after KTX was associated with a lower risk of sustained eGFR reduction. CONCLUSION: GLP-1 RAs resulted in lower eGFR reduction compared with non-GLP-1 RAs and may contribute to better kidney graft survival after KTX.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Sato T, Azuma Y, Ozone C, et al. Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes. J Clin Endocrinol Metab. 2023. PMID: 36974363. doi:10.1210/clinem/dgad177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。